摘要
目的观察头孢哌酮舒巴坦(SCF)联合阿奇霉素(AZM)治疗老年重症肺炎伴细菌感染的临床疗效。方法选取安庆市立医院2017年5月至2019年5月收治的伴细菌感染老年重症肺炎患者100例,按随机数字表法分为治疗组和对照组,各50例。两组患者均予常规治疗,并予注射用头孢哌酮钠舒巴坦钠静脉滴注,治疗组患者加用注射用阿奇霉素。两组均连续治疗14 d。结果治疗组总有效率为88.00%,细菌清除率为88.10%,显著高于对照组的64.00%和42.50%(P<0.05);治疗组患者体温、痰液颜色、白细胞计数及湿罗音复常时间均显著短于对照组(P<0.05);与治疗前比较,两组患者治疗后的血清炎性因子水平均显著降低,且治疗组显著低于对照组(P<0.05);治疗组与对照组不良反应发生率相当(8.00%比10.00%,χ2=0.122,P=0.727>0.05)。结论相对于单用SCF,SCF联合AZM治疗伴细菌感染老年重症肺炎,患者临床症状指标复常时间更短,炎性指标改善程度更显著。
Objective To observe the clinical efficacy of cefoperazone-sulbactam(SCF)combined with azithromycin(AZM)on elderly patients with severe pneumonia and bacterial infection.Methods A total of 100 elderly patients with severe pneumonia who were admitted to the Anqing City Hospital from May 2017 to May 2019 were selected and divided into the treatment group and control group by random number table method,50 cases in each group.Both groups were was given routine treatment and SCF,while the treatment group was added with AZM.Both groups were continuously treated for 14 d.Results The total effective rate in the treatment group was 88.00%,and the bacterial clearance rate was 88.10%,which were significantly higher than 64.00%and 42.50%in the control group(P<0.05).The temperature,sputum color,white blood cell count and moist rale recovery time in the treatment group were significantly lower than the control group(P<0.05).Compared with before treatment,the serum inflammatory factor levels of the two groups were significantly reduced,and the levels in the treatment group were significantly lower than the control group(P<0.05).The incidence of adverse reactions in the treatment group and the control group was similar(8.00%vs.10.00%,χ~2=0.122,P=0.727>0.05).Conclusion Compared with using SCF alone,SCF combined with AZM for elderly patients with severe pneumonia and bacterial infection can shorten the clinical symptom recovery time and have more significant improvement of inflammatory indexes.
作者
李长东
黄利娟
张立明
LI Changdong;HUANG Lijuan;ZHANG Liming(Anqing City Hospital,Anqing,Anhui,China 246003;Hefei First People′s Hospital,Hefei,Anhui,China 230061)
出处
《中国药业》
CAS
2020年第12期67-69,共3页
China Pharmaceuticals
基金
安徽省自然科学基金[1708085MH162]。
关键词
头孢哌酮舒巴坦
阿奇霉素
老年
重症肺炎
细胞感染
临床疗效
cefoperazone-sulbactam
azithromycin
elderly
severe pneumonia
bacterial infection
clinical efficacy
